FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 350:971-980 March 4, 2004 Number 10 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Editorial by Balow, J. E. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Long-term therapy with cyclophosphamide enhances renal survival in patients with proliferative lupus nephritis; however, the beneficial effect of cyclophosphamide must be weighed against its considerable toxic effects.

Methods Fifty-nine patients with lupus nephritis (12 in World Health Organization class III, 46 in class IV, and 1 in class Vb) received induction therapy consisting of a maximum of seven monthly boluses of intravenous cyclophosphamide (0.5 to 1.0 g per square meter of body-surface area) plus corticosteroids. Subsequently, the patients were randomly assigned to one of three maintenance therapies: quarterly intravenous injections of cyclophosphamide, oral azathioprine (1 to 3 mg per kilogram of body weight per day), or oral mycophenolate mofetil (500 to 3000 mg per day) for one to three years. The base-line characteristics of the three groups were similar, with the exception that the chronicity index was 1.9 points lower in the cyclophosphamide group than in the mycophenolate mofetil group (P=0.009).

Results During maintenance therapy, five patients died (four in the cyclophosphamide group and one in the mycophenolate mofetil group), and chronic renal failure developed in five (three in the cyclophosphamide group and one each in the azathioprine and mycophenolate mofetil groups). The 72-month event-free survival rate for the composite end point of death or chronic renal failure was higher in the mycophenolate mofetil and azathioprine groups than in the cyclophosphamide group (P=0.05 and P=0.009, respectively). The rate of relapse-free survival was higher in the mycophenolate mofetil group than in the cyclophosphamide group (P=0.02). The incidence of hospitalization, amenorrhea, infections, nausea, and vomiting was significantly lower in the mycophenolate mofetil and azathioprine groups than in the cyclophosphamide group.

Conclusions For patients with proliferative lupus nephritis, short-term therapy with intravenous cyclophosphamide followed by maintenance therapy with mycophenolate mofetil or azathioprine appears to be more efficacious and safer than long-term therapy with intravenous cyclophosphamide.

Source Information

From the Dialysis Unit (G.C.) and the Electron Microscopy Unit (V.P.), Veterans Affairs Medical Center and University of Miami; and the Divisions of Nephrology (B.L., O.L., P.O., D.R.) and Rheumatology and Immunology (E.T.), University of Miami — both in Miami.

Address reprint requests to Dr. Contreras at the Division of Nephrology, 1600 NW 10th Ave. R-126, Miami, FL 33136, or at gcontrer{at}med.miami.edu.

Full Text of this Article

Related Letters:

Sequential Therapies for Proliferative Lupus Nephritis
Yee C.-S., Gordon C., Gelber A. C., Christopher-Stine L., Fine D. M., Farhey Y., Hess E., Contreras G., Lenz O., Roth D.
Extract | Full Text | PDF  
N Engl J Med 2004; 350:2518-2520, Jun 10, 2004. Correspondence

This article has been cited by other articles:

• Boletis, J. N., Marinaki, S., Skalioti, C., Lionaki, S. S., Iniotaki, A., Sfikakis, P. P. (2009). Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study. Nephrol Dial Transplant 24: 2157-2160 [Abstract] [Full Text]  
• Appel, G. B., Contreras, G., Dooley, M. A., Ginzler, E. M., Isenberg, D., Jayne, D., Li, L.-S., Mysler, E., Sanchez-Guerrero, J., Solomons, N., Wofsy, D., the Aspreva Lupus Management Study Group, (2009). Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis. J. Am. Soc. Nephrol. 20: 1103-1112 [Abstract] [Full Text]  
• Roland, M, Barbet, C, Paintaud, G, Magdelaine-Beuzelin, C, Diot, E, Halimi, J., Lebranchu, Y, Nivet, H, Buchler, M (2009). Mycophenolate mofetil in patients with systemic lupus erythematosus: a prospective pharmacokinetic study. Lupus 18: 441-447 [Abstract]  
• Gordon, C, Bertsias, G, Ioannidis, J P A, Boletis, J, Bombardieri, S, Cervera, R, Dostal, C, Font, J, Gilboe, I-M, Houssiau, F, Huizinga, T W J, Isenberg, D, Kallenberg, C G M, Khamashta, M A, Piette, J-C, Schneider, M, Smolen, J S, Sturfelt, G, Tincani, A, Van Vollenhoven, R, Boumpas, D T (2009). EULAR points to consider for conducting clinical trials in systemic lupus erythematosus. Ann Rheum Dis 68: 470-476 [Abstract] [Full Text]  
• Bertsias, G K, Ioannidis, J P A, Boletis, J, Bombardieri, S, Cervera, R, Dostal, C, Font, J, Gilboe, I M, Houssiau, F, Huizinga, T, Isenberg, D, Kallenberg, C G M, Khamashta, M, Piette, J C, Schneider, M, Smolen, J, Sturfelt, G, Tincani, A, van Vollenhoven, R, Boumpas, D T, Gordon, C (2009). EULAR points to consider for conducting clinical trials in systemic lupus erythematosus: literature based evidence for the selection of endpoints. Ann Rheum Dis 68: 477-483 [Abstract] [Full Text]  
• Karim, M. Y., Pisoni, C. N., Khamashta, M. A. (2009). Update on immunotherapy for systemic lupus erythematosus--what's hot and what's not!. Rheumatology (Oxford) 48: 332-341 [Abstract] [Full Text]  
• Masood, S, Jayne, D, Karim, Y (2009). Beyond immunosuppression - challenges in the clinical management of lupus nephritis. Lupus 18: 106-115 [Abstract]  
• RIVERA, T. L., BELMONT, H. M., MALANI, S., LATORRE, M., BENTON, L., WEISSTUCH, J., BARISONI, L., TSENG, C.-E, IZMIRLY, P. M., BUYON, J. P., ASKANASE, A. D. (2009). Current Therapies for Lupus Nephritis in an Ethnically Heterogeneous Cohort. The Journal of Rheumatology 36: 298-305 [Abstract] [Full Text]  
• Bargman, J. M. (2009). How did cyclophosphamide become the drug of choice for lupus nephritis?. Nephrol Dial Transplant 24: 381-384 [Full Text]  
• Benseler, S. M., Bargman, J. M., Feldman, B. M., Tyrrell, P. N., Harvey, E., Hebert, D., Silverman, E. D. (2009). Acute renal failure in paediatric systemic lupus erythematosus: treatment and outcome. Rheumatology (Oxford) 48: 176-182 [Abstract] [Full Text]  
• TSE, K. C., TANG, C. S.O., LAM, M. F., YAP, D. Y.H., CHAN, T. M. (2009). Cost Comparison Between Mycophenolate Mofetil and Cyclophosphamide-Azathioprine in the Treatment of Lupus Nephritis. The Journal of Rheumatology 36: 76-81 [Abstract] [Full Text]  
• ASKANASE, A. D., WALLACE, D. J., WEISMAN, M. H., TSENG, C.-E, BERNSTEIN, L., BELMONT, H. M., SEIDMAN, E., ISHIMORI, M., IZMIRLY, P. M., BUYON, J. P. (2009). Use of Pharmacogenetics, Enzymatic Phenotyping, and Metabolite Monitoring to Guide Treatment with Azathioprine in Patients with Systemic Lupus Erythematosus. The Journal of Rheumatology 36: 89-95 [Abstract] [Full Text]  
• Lv, J., Zhang, H., Cui, Z., Su, T., Zhang, Y., Wang, H. (2008). Delayed severe pneumonia in mycophenolate mofetil-treated patients with IgA nephropathy. Nephrol Dial Transplant 23: 2868-2872 [Abstract] [Full Text]  
• Traitanon, O, Avihingsanon, Y, Kittikovit, V, Townamchai, N, Kanjanabuch, T, Praditpornsilpa, K, Wongchinasri, J, Tungsanga, K, Eiam-Ong, S (2008). Efficacy of enteric-coated mycophenolate sodium in patients with resistant-type lupus nephritis: a prospective study. Lupus 17: 744-751 [Abstract]  
• Chan, T. (2008). Mycophenolate mofetil in the treatment of lupus nephritis - 7 years on. Lupus 17: 617-621  
• F, L., Y, T., X, P., L, W., H, W., Z, S., H, Z., Z, H. (2008). A prospective multicentre study of mycophenolate mofetil combined with prednisolone as induction therapy in 213 patients with active lupus nephritis. Lupus 17: 622-629 [Abstract]  
• Joy, M. S., La, M., Bo Xiao, (2008). Individualizing Therapy in Patients With Chronic Kidney Disease. Journal of Pharmacy Practice 21: 225-236 [Abstract]  
• Houssiau, F., Ginzler, E. (2008). Current treatment of lupus nephritis. Lupus 17: 426-430 [Abstract]  
• Bertsias, G, Ioannidis, J P A, Boletis, J, Bombardieri, S, Cervera, R, Dostal, C, Font, J, Gilboe, I M, Houssiau, F, Huizinga, T, Isenberg, D, Kallenberg, C G M, Khamashta, M, Piette, J C, Schneider, M, Smolen, J, Sturfelt, G, Tincani, A, van Vollenhoven, R, Gordon, C, Boumpas, D T (2008). EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 67: 195-205 [Abstract] [Full Text]  
• Kasitanon, N., Petri, M., Haas, M., Magder, L.S., Fine, D.M. (2008). Mycophenolate mofetil as the primary treatment of membranous lupus nephritis with and without concurrent proliferative disease: a retrospective study of 29 cases. Lupus 17: 40-45 [Abstract]  
• Sinclair, A., Appel, G., Dooley, M.A., Ginzler, E., Isenberg, D., Jayne, D., Wofsy, D., Solomons, N. (2007). Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS). Lupus 16: 972-980 [Abstract]  
• Wells, A. U., Latsi, P., McCune, W. J. (2007). Daily Cyclophosphamide for Scleroderma: Are Patients with the Most to Gain Underrepresented in this Trial?. Am. J. Respir. Crit. Care Med. 176: 952-953 [Full Text]  
• Petri, M. (2007). Disease activity assessment in SLE: do we have the right instruments?. Ann Rheum Dis 66: iii61-iii64 [Abstract] [Full Text]  
• de Castro, W.P., Morales, J.V., Wagner, M.B., Graudenz, M., Edelweiss, M.I., Goncalves, L.F. (2007). Hypertension and Afro-descendant ethnicity: a bad interaction for lupus nephritis treated with cyclophosphamide?. Lupus 16: 724-730 [Abstract]  
• El Sebaaly, Z., Charpentier, B., Snanoudj, R. (2007). Fetal malformations associated with mycophenolate mofetil for lupus nephritis. Nephrol Dial Transplant 22: 2722-2722 [Full Text]  
• Contreras, G., Sosnov, J. (2007). Role of Mycophenolate Mofetil in the Treatment of Lupus Nephritis. CJASN 2: 879-882 [Full Text]  
• Ruperto, N., Bazso, A., Ravelli, A., Malattia, C., Filocamo, G., Pistorio, A., Rodriguez Lozano, A.L., Viola, S., Martini, A. (2007). Review: The Paediatric Rheumatology International Trials Organization (PRINTO). Lupus 16: 670-676 [Abstract]  
• MacDermott, E., Adams, A., Lehman, T. (2007). Review: Systemic lupus erythematosus in children: current and emerging therapies. Lupus 16: 677-683 [Abstract]  
• Ranchin, B., Fargue, S. (2007). Review: New treatment strategies for proliferative lupus nephritis: keep children in mind!. Lupus 16: 684-691 [Abstract]  
• Zhu, B., Chen, N., Lin, Y., Ren, H., Zhang, W., Wang, W., Pan, X., Yu, H. (2007). Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials. Nephrol Dial Transplant 22: 1933-1942 [Abstract] [Full Text]  
• Zandi, M. S, Coles, A. J (2007). Notes on the kidney and its diseases for the neurologist. J. Neurol. Neurosurg. Psychiatry 78: 444-449 [Abstract] [Full Text]  
• Stassen, P. M., Kallenberg, C. G. M., Stegeman, C. A. (2007). Use of mycophenolic acid in non-transplant renal diseases. Nephrol Dial Transplant 22: 1013-1019 [Full Text]  
• Houssiau, F (2007). Thirty years of cyclophosphamide: assessing the evidence. Lupus 16: 212-216 [Abstract]  
• Haubitz, M (2007). Exploring new territory: the move towards individualised treatment. Lupus 16: 227-231 [Abstract]  
• Nihtyanova, S. I., Brough, G. M., Black, C. M., Denton, C. P. (2007). Mycophenolate mofetil in diffuse cutaneous systemic sclerosis--a retrospective analysis. Rheumatology (Oxford) 46: 442-445 [Abstract] [Full Text]  
• Pisoni, C. N., Cuadrado, M. J., Khamashta, M. A., Hughes, G. R. V., D'Cruz, D. P. (2007). Mycophenolate mofetil treatment in resistant myositis. Rheumatology (Oxford) 46: 516-518 [Abstract] [Full Text]  
• Alperovich, G, Rama, I, Lloberas, N, Franquesa, M, Poveda, R, Goma, M, Herrero-Fresneda, I, Cruzado, J M, Bolanos, N, Carrera, M, Grinyo, J M, Torras, J (2007). New immunosuppresor strategies in the treatment of murine lupus nephritis. Lupus 16: 18-24 [Abstract]  
• van Leuven, S I, Kastelein, J J P, Hayden, M R, Stroes, E S (2006). Mycophenolate mofetil as an immunomodulatory silver bullet in atherogenesis?. Lupus 15: 11-17 [Abstract]  
• Doria, A, Iaccarino, L, Arienti, S, Rampudda, M E, Canova, M G, Rondinone, R, Todesco, S (2006). Mycophenolate mofetil and systemic lupus erythematosus. Lupus 15: 44-54 [Abstract]  
• Sinclair, A, Baildon, R (2006). Mycophenolate mofetil: an overview. Lupus 15: 70-77  
• Appel, L. J. (2006). A Primer on the Design, Conduct, and Interpretation of Clinical Trials. CJASN 1: 1360-1367 [Abstract] [Full Text]  
• Ruiz-Irastorza, G, Egurbide, M-V, Pijoan, J-I, Garmendia, M, Villar, I, Martinez-Berriotxoa, A, Erdozain, J-G, Aguirre, C (2006). Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 15: 577-583 [Abstract]  
• Moroni, G., Doria, A., Mosca, M., Alberighi, O. D. C., Ferraccioli, G., Todesco, S., Manno, C., Altieri, P., Ferrara, R., Greco, S., Ponticelli, C. (2006). A Randomized Pilot Trial Comparing Cyclosporine and Azathioprine for Maintenance Therapy in Diffuse Lupus Nephritis over Four Years. CJASN 1: 925-932 [Abstract] [Full Text]  
• Bihl, G. R., Petri, M., Fine, D. M. (2006). Kidney biopsy in lupus nephritis: look before you leap. Nephrol Dial Transplant 21: 1749-1752 [Full Text]  
• Preddie, D. C., Markowitz, G. S., Radhakrishnan, J., Nickolas, T. L., D'Agati, V. D., Schwimmer, J. A., Gardenswartz, M., Rosen, R., Appel, G. B. (2006). Mycophenolate Mofetil for the Treatment of Interstitial Nephritis. CJASN 1: 718-722 [Abstract] [Full Text]  
• Ponticelli, C. (2006). New Therapies for Lupus Nephritis. CJASN 1: 863-868 [Full Text]  
• Mok, C C, Mak, A, To, C H (2006). Mycophenolate mofetil for lupus related myelopathy.. Ann Rheum Dis 65: 971-973 [Full Text]  
• D'Cruz, D. P (2006). Systemic lupus erythematosus.. BMJ 332: 890-894 [Full Text]  
• Dooley, M A (2006). Mycophenylate mofetil: what role in the treatment of lupus?. Lupus 15: 179-182 [Abstract]  
• Karassa, F. B., Killen, J. P., Ginzler, E. M., Dooley, M. A., Kim, M. Y. (2006). Mycophenolate mofetil or intravenous cyclophosphamide in lupus nephritis.. NEJM 354: 764-765 [Full Text]  
• Joy, M. S., Hogan, S. L., Jennette, J. C., Falk, R. J., Nachman, P. H. (2005). A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. Nephrol Dial Transplant 20: 2725-2732 [Abstract] [Full Text]  
• Ginzler, E. M., Dooley, M. A., Aranow, C., Kim, M. Y., Buyon, J., Merrill, J. T., Petri, M., Gilkeson, G. S., Wallace, D. J., Weisman, M. H., Appel, G. B. (2005). Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis.. NEJM 353: 2219-2228 [Abstract] [Full Text]  
• McCune, W. J. (2005). Mycophenolate Mofetil for Lupus Nephritis.. NEJM 353: 2282-2284 [Full Text]  
• Dasgupta, N, Gelber, A C, Racke, F, Fine, D M (2005). Central nervous system lymphoma associated with mycophenolate mofetil in lupus nephritis. Lupus 14: 910-913 [Abstract]  
• Karim, M. Y., Pisoni, C. N., Ferro, L., Tungekar, M. F., Abbs, I. C., D'Cruz, D. P., Khamashta, M. A., Hughes, G. R. V. (2005). Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy. Rheumatology (Oxford) 44: 1317-1321 [Abstract] [Full Text]  
• Fine, D. M. (2005). Pharmacological Therapy of Lupus Nephritis. JAMA 293: 3053-3060 [Abstract] [Full Text]  
• Illei, G G (2005). On the road to the optimal treatment of lupus nephritis: are we there yet?. Lupus 14: 263-264  
• Chan, T M, Tse, K C, Tang, C S., Lai, K N, Li, F K (2005). Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. Lupus 14: 265-272 [Abstract]  
• Chan, T.-M., Tse, K.-C., Tang, C. S.-O., Mok, M.-Y., Li, F.-K., for the Hong Kong Nephrology Study Group, (2005). Long-Term Study of Mycophenolate Mofetil as Continuous Induction and Maintenance Treatment for Diffuse Proliferative Lupus Nephritis. J. Am. Soc. Nephrol. 16: 1076-1084 [Abstract] [Full Text]  
• Pisoni, C N, Karim, Y, Cuadrado, M J (2005). Mycophenolate mofetil and systemic lupus erythematosus: an overview. Lupus 14: s9-s11 [Abstract]  
• Chan, T M (2005). Lupus nephritis: induction therapy. Lupus 14: s27-s32 [Abstract]  
• Contreras, G, Tozman, E, Nahar, N., Metz, D. (2005). Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide. Lupus 14: s33-s38 [Abstract]  
• Gorman, C., Bhatia, A., Rahman, A. (2005). This house believes that low-dose intravenous cyclophosphamide is superior to standard high-dose regimes for treatment of lupus nephritis. Rheumatology (Oxford) 44: 398-401 [Full Text]  
• D'Cruz, D. P, Hughes, G. R V (2005). The treatment of lupus nephritis. BMJ 330: 377-378 [Full Text]  
• Mok, C C (2005). Prognostic factors in lupus nephritis. Lupus 14: 39-44 [Abstract]  
• Sidiropoulos, P I, Kritikos, H D, Boumpas, D T (2005). Lupus nephritis flares. Lupus 14: 49-52 [Abstract]  
• Houssiau, F A (2005). Cyclophosphamide in lupus nephritis. Lupus 14: 53-58 [Abstract]  
• Ginzler, E M, Aranow, C (2005). Mycophenolate mofetil in lupus nephritis. Lupus 14: 59-64 [Abstract]  
• Tahir, H, Isenberg, D A (2005). Novel therapies in lupus nephritis. Lupus 14: 77-82 [Abstract]  
• Pisoni, C., Karim, Y., Cuadrado, M. (2005). Mycophenolate mofetil and systemic lupus erythematosus: an overview. Lupus 14: s9-s11 [Abstract]  
• Chan, T. (2005). Lupus nephritis: induction therapy. Lupus 14: s27-s32 [Abstract]  
• Contreras, G., Tozman, E., Nahar, N., Metz, D. (2005). Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide. Lupus 14: s33-s38 [Abstract]  
• Raptopoulou, A., Sidiropoulos, P., Boumpas, D. T (2004). Ovarian failure and strategies for fertility preservation in patients with systemic lupus erythematosus. Lupus 13: 887-890  
• Houssiau, F. A. (2004). Management of Lupus Nephritis: An Update. J. Am. Soc. Nephrol. 15: 2694-2704 [Full Text]  
• Vasoo, S (2004). First international meeting on mycophenolate mofetil: an advance in the treatment of lupus 27 April 2004, St Thomas' Hospital, London, UK. Lupus 13: 543-545  
• Yee, C.-S., Gordon, C., Gelber, A. C., Christopher-Stine, L., Fine, D. M., Farhey, Y., Hess, E., Contreras, G., Lenz, O., Roth, D. (2004). Sequential Therapies for Proliferative Lupus Nephritis. NEJM 350: 2518-2520 [Full Text]  
• Balow, J. E., Austin, H. A. III (2004). Maintenance Therapy for Lupus Nephritis -- Something Old, Something New. NEJM 350: 1044-1046 [Full Text]